ORIC
Oric Pharmaceuticals, Inc. Common Stock
stockNASDAQ
oric pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. its lead product candidate is oric-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. the company's second product candidate is oric-533, an orally bioavailable small molecule inhibitor of cd73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. it is also developing multiple precision medicines targeting other cancer resistance mechanisms. the company was founded in 2014 and is headquartered in south san francisco, california.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 13.27 | 2026-09-28 | -8.06% | -4.009 |
| 1M | 12.86 | 2026-09-04 | -5.13% | -0.007 |
| 3M | 10.91 | 2026-07-06 | +11.82% | 2.393 |
| 6M | 8.91 | 2026-04-06 | +36.92% | 1.792 |
| 1Y | 14.41 | 2025-10-06 | -15.34% | 1.348 |
| 2Y | 9.61 | 2024-10-04 | +26.95% | — |
| 5Y | 19.72 | 2021-10-05 | -38.13% | 1.191 |
Oric Pharmaceuticals, Inc. Common Stock (NASDAQ:ORIC) stock price today is $12.20, and today's volume is 1,232,085. ORIC is down 2.556% today. The 30 day average volume is 1.38M. ORIC market cap is $1.26B with 103.65M shares outstanding.